Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun;53(2):104233.
doi: 10.1016/j.lpm.2024.104233. Epub 2024 Apr 16.

Pharmacotherapy and noninvasive neurostimulation for neuropathic pain

Affiliations
Review

Pharmacotherapy and noninvasive neurostimulation for neuropathic pain

Annachiara Spagna et al. Presse Med. 2024 Jun.

Abstract

Neuropathic pain poses a significant challenge due to its complex mechanisms, necessitating specific treatments. In recent decades, significant progress has been made in the clinical research of neuropathic pain, marking a shift from empirical strategies to evidence-based medicine in its management. This review outlines both pharmacological and non-pharmacological interventions. Antidepressants (tricyclic and serotonin-noradrenaline reuptake inhibitors), antiepileptics (gabapentin, pregabalin), and topical agents constitute the main pharmacological treatments. These approaches target peripheral or central mechanisms associated with neuropathic pain. Noninvasive neurostimulation, including transcutaneous electrical nerve stimulation (TENS) and repetitive transcranial magnetic stimulation (rTMS), provides non-pharmacological alternatives. However, challenges persist in effectively targeting existing medications and developing drugs that act on novel targets, necessitating innovative therapeutic strategies.

Keywords: Antidepressants; Antiepileptics; Neuropathic pain; Neurostimulation; Noninvasive brain stimulation; Opioids; Pharmacological treatments; Topical analgesics.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Over the past 3 years, Nadine Attal has received fees for advisory boards or speakers bureau from Pfizer, Viatris, Novartis, Grunenthal, Upsa, Merz, Biogen outside the submitted work. Annachiara Spagna has nothing to disclose.

MeSH terms

LinkOut - more resources